Altimmune (ALT) Income from Continuing Operations (2010 - 2026)
Altimmune's (ALT) quarterly Income from Continuing Operations came in at 22563000.0 in Q1 2026, down 15.26% year-on-year from 26627523.06 in Q1 2025, and down 129.74% on a QoQ basis from 75855000.0 in Q4 2025.
Altimmune (ALT) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Altimmune (ALT) has 17 years of Income from Continuing Operations data on file, last reported at 22563000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 15.26% year-over-year to 22563000.0 in Q1 2026; TTM through Mar 2026 was 12132000.0, a 113.44% increase from a year earlier, with the FY2025 full-year figure at 15120000.0, up 120.13% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 22563000.0, down from 75855000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for ALT reached as high as 75855000.0 in Q4 2025 and fell as low as 31641000.0 in Q4 2023.
- Historically, Income from Continuing Operations has averaged 15574882.35 across 5 years, with a median of 20671000.0 in 2023.
- Across the five-year window, Income from Continuing Operations sank 228.09% in 2023 and surged 427.24% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 9644000.0 in 2022, then sank by 228.09% to 31641000.0 in 2023, then increased by 26.74% to 23180000.0 in 2024, then jumped by 427.24% to 75855000.0 in 2025, then tumbled by 129.74% to 22563000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 22563000.0 in Q1 2026, 75855000.0 in Q4 2025, and 19014000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Altimmune | 7.96 Mn | 7.96 Mn | - | -22.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.56 Mn |
| Dec 31, 2025 | 75.86 Mn |
| Sep 30, 2025 | -19.01 Mn |
| Jun 30, 2025 | -22.15 Mn |
| Mar 31, 2025 | -19.58 Mn |
| Dec 31, 2024 | -23.18 Mn |
| Sep 30, 2024 | -22.85 Mn |
| Jun 30, 2024 | -24.64 Mn |
| Mar 31, 2024 | -24.39 Mn |
| Dec 31, 2023 | -31.64 Mn |
| Sep 30, 2023 | -20.67 Mn |
| Jun 30, 2023 | -16.90 Mn |
| Mar 31, 2023 | -20.19 Mn |
| Dec 31, 2022 | -9.64 Mn |
| Sep 30, 2022 | -23.52 Mn |
| Jun 30, 2022 | -20.13 Mn |
| Mar 31, 2022 | -19.58 Mn |
| Dec 31, 2021 | -5.38 Mn |
| Sep 30, 2021 | -33.51 Mn |
| Jun 30, 2021 | -24.83 Mn |